1. People's Republic of China Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Guangdong Marubi Biotechnology Co., Ltd.

Guangdong Marubi Biotechnology Co., Ltd.

603983.SS
Guangdong Marubi Biotechnology Co., Ltd.CN flagShanghai Stock Exchange
31.22
CNY
+0.10
- -
12.52BMarket Cap
Guangdong Marubi Biotechnology Co., Ltd.
603983.SS
(Shanghai Stock Exchange)

Recent

price

31.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
4.54
2.72
2.97
3.3
3.33
3.77
4.36
4.79
4.36
4.47
4.28
5.58
7.39
8.67
6.96
Revenue per Share
- -
1.04
0.61
0.75
0.78
0.64
0.87
1.15
1.37
1.16
0.62
0.43
0.65
0.85
0.62
0.38
Basic EPS, GAAP
- -
0.82
0.72
0.92
0.73
0.57
0.98
1.4
1.22
-0.97
-0.31
-0.15
0.21
-0.04
0.17
-0.39
Free Cash Flow per Basic Share
- -
0.56
0.28
0.33
0.47
0.33
0.5
- -
- -
0.39
0.35
0.19
0.27
0.78
0.75
0.74
Dividend per Share
- -
1.06
1.12
1.47
1.68
1.93
2.27
3.3
4.58
5.05
5.33
5.5
5.98
6.02
5.93
6.11
Book Value per Share
- -
1.21
1.23
1.64
1.95
2.23
2.63
3.75
7.06
7.45
5.99
6.18
6.76
6.84
7.52
7.68
Tangible Book Value per Share
- -
180
358
362
361
363
359
361
376
400
400
405
399
402
399
404
Basic Weighted Avg Shares
613
815
974
1,076
1,191
1,208
1,352
1,576
1,801
1,745
1,787
1,732
2,226
2,970
3,459
2,813
Sales/Revenue/Turnover
32.34
25.69
25.11
27.8
25.04
20.34
25.76
28.86
31.73
27.94
14
10.02
9.01
12.12
7.34
7.04
Operating Margin (%)
1
2
2
9
14
15
15
15
16
13
20
27
25
28
63
- -
Depreciation Expense
167
187
219
271
281
232
312
415
515
464
248
174
259
342
247
155
Net Income, GAAP
16.31
15.31
15.37
14.87
14.73
15.11
14.93
15.27
16.48
18.32
22.1
18.95
12.46
10.06
16.57
22.11
Effective Tax Rate (%)
27.28
22.93
22.45
25.23
23.63
19.22
23.07
26.35
28.59
26.61
13.87
10.06
11.66
11.5
7.15
5.51
Profit Margin (%)
-5
14
163
250
367
510
681
1,082
2,366
1,893
1,399
1,569
1,520
1,358
1,037
1,136
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
15
160
3
2
2
2
LT Debt
148
235
453
604
716
828
960
1,382
2,670
3,000
3,158
3,253
3,419
3,447
3,394
3,493
Total Equity
- -
85.94
58.16
44.52
34.74
24.72
31.2
31.48
22.86
13.46
6.07
4.12
4.81
8.09
5.22
3.78
Return on Invested Capital (%)
- -
114.92
71.96
56.65
46.38
34.51
40.63
40.99
35.43
24.06
11.66
7.67
9.36
11.67
8.2
5.29
Return on Capital (%)
- -
117.08
73.55
57.95
49.34
35.46
41.18
41.43
35.37
24.81
11.94
7.99
11.24
14.21
10.33
6.17
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
396
468
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
401
401
Market Capitalization
15,808
13,167
10,708

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
2,236
2,313
Cash, Cash Equivalents & STI
- -
1,639
1,659
Accounts Receivable, Net
- -
37
30
Inventories
- -
233
225
Total Current Liabilities
- -
1,199
1,177
Payables & Accruals
- -
- -
- -
ST Debt
- -
396
468
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.38%
2.53%
-1.52%
Free Cash Flow
-110.51%
-200.8%
-533.06%
Net Income, GAAP
4.08%
-4.67%
-27.63%
Sales/Revenue/Turnover
11.88%
15.55%
16.48%
Total Cash Common Dividend
- -
34.8%
-3.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
661
691
600
1,017
2,970
2025
847
923
- -
1,009
3,459
2026
881
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
- -
- -
- -
0.85
2025
0.34
- -
- -
- -
0.62
2026
0.25
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.78
2025
- -
- -
- -
- -
0.75
2026
- -
- -
- -
- -
- -
Similar Companies
Evergreen Products Group Limited (1962.HK)
Kolmar BNH Co., Ltd. (200130.KQ)
Henkel AG & Co. KGaA (HEN3.SW)
Maywufa Company Ltd. (1731.TW)
Somnigroup International Inc (SGI)
BWX Limited (BWXXF)
Business
Guangdong Marubi Biotechnology Co., Ltd. is a China-based company primarily engaged in the research, development, design, production, sale, and service of various cosmetics. Its core product portfolio includes eye care products; skin cleansing products; skin care products such as creams, lotions, and masks; and makeup products. The company markets these products under several brand names including Marubi, Cac, and Passional Lover, operating mainly in the domestic Chinese market. Founded in 2002 and headquartered in Guangzhou, Guangdong Province, Marubi has established itself as a significant player in the cosmetics industry within China. Recent developments include a strategic partnership with the German chemicals company Evonik, aimed at advancing the development of the Chinese cosmetics industry through collaboration in raw materials, research, and formulation innovation. This alliance focuses on leveraging mutual expertise to deliver high-performance and sustainable cosmetic products, aligning with Marubi’s commitment to quality and international expansion. Additionally, Marubi plans to issue H-shares and seek a listing on the Hong Kong Stock Exchange to strengthen its capital position and enhance overseas financing capabilities. These moves mark significant strategic expansions beyond its traditional market scope, positioning the company for broader growth and competitiveness in the global cosmetics industry. Guangdong Marubi Biotechnology operates primarily within the cosmetics sector targeting consumer markets interested in skincare, eye care, and makeup products. The company maintains a comprehensive value chain, from research and development to production and sales, encompassing a broad range of cosmetic formulations and applications. Its product innovation and market responsiveness are supported by its collaboration with global chemical industry leaders, reflecting its strategic commitment to advancing product efficacy and sustainability. The company’s headquarters and manufacturing facilities are located in Guangzhou, China, and it employs over one thousand people, supporting a substantial operational scale. This profile reflects Marubi’s evolving business model and market positioning as it pursues growth through partnerships and capital market initiatives.